<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02000089</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00087754</org_study_id>
    <nct_id>NCT02000089</nct_id>
  </id_info>
  <brief_title>The Cancer of the Pancreas Screening-5 CAPS5)Study</brief_title>
  <acronym>CAPS5</acronym>
  <official_title>The Cancer of the Pancreas Screening-5 CAPS5)Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ChiRhoClin, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Johns Hopkins clinical research office quality assurance group will monitor and audit this
      study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal
      monitoring at their site.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Sub Investigator at each site will be responsible for internal monitoring at their site.
      The site sub Investigator and study team will report any serious adverse events to Principal
      Investigator and annually report adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate pancreatic juice for early cancer markers.</measure>
    <time_frame>8 years</time_frame>
    <description>Aim #1: To evaluate pancreatic fluid mutations and circulating pancreatic epithelial cells as accurate markers of neoplasia by comparing their prevalence in cases with sporadic pancreatic neoplasia to healthy and disease controls.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare pancreas juice with pancreas cyst fluid</measure>
    <time_frame>8 years</time_frame>
    <description>Aim #2: To compare the prevalence of pancreatic fluid mutations and circulating pancreatic epithelial cells among a prospective cohort of individuals with sporadic pancreatic cysts undergoing pancreatic surveillance.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Time disease progression and prevalence</measure>
    <time_frame>8 years</time_frame>
    <description>Aim #3: To determine the prevalence of pancreatic lesions, pancreatic fluid mutations and circulating pancreatic epithelial cells among a large cohort of high-risk individuals undergoing pancreatic screening and surveillance of a new cohort in which screening is begun at age &gt;55.</description>
  </other_outcome>
  <number_of_groups>9</number_of_groups>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>Pancreas Cancer</condition>
  <condition>Peutz-Jeghers Syndrome (PJS)</condition>
  <condition>Gene Mutation</condition>
  <condition>Germline Mutation Carrier</condition>
  <condition>Lynch Syndrome</condition>
  <arm_group>
    <arm_group_label>Familial pancreas cancer relatives</arm_group_label>
    <description>High Risk Group 2 (familial pancreatic cancer relatives):
&gt; 55 years old or 10 years younger than the age of youngest relative with pancreatic cancer, and
come from a family with 2 or more members with a history of pancreatic cancer (2 of which have a first-degree relationship consistent with familial pancreatic cancer), and
have a first-degree relationship with at least one of the relatives with pancreatic cancer.
If there are 2 or more affected blood relatives, at least 1 must be a first-degree relative of the individual being screened</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1 germline mutation carrier</arm_group_label>
    <description>High Risk Group 3 (Group 1 germline mutation carriers with an associated with an estimated lifetime risk of pancreatic cancer of ~10% or higher):
a. &gt; 50 years old or 10 years younger than the age of the youngest relative with pancreatic cancer, and b. The Patient is a carrier of a confirmed FAMMM (p16/CDKN2A), BRCA2, or PALB2 mutation, and there is 1 or more pancreatic cancer diagnoses in the family, one of whom is a first- or second-degree relative of the subject to be screened.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 germline mutation carrier</arm_group_label>
    <description>High Risk Group 4 (Group 2 germline mutation carriers with an associated with an estimated lifetime risk of pancreatic cancer of ~5%):
&gt; 55 years old or 10 years younger than the age of the youngest relative with pancreatic cancer, and
The patient is a carrier of a confirmed BRCA1, ATM or HNPCC (hereditary non-polyposis colorectal cancer or Lynch syndrome, hMLH1, hMSH2, PMS1, hMSH6, EpCAM) gene mutation, and there is &gt; 1 pancreatic cancer in the family, one of whom is a first- or second-degree relative of the subject to be screened.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hereditary pancreatitis</arm_group_label>
    <description>High risk group 5 (hereditary pancreatitis) with confirmed gene mutations that predispose to chronic pancreatitis, such as PRSS1, PRSS2, CTRC) and age 50 years or older (these patients have an estimated lifetime risk for pancreatic cancer of 40%) or twenty-years since their first attack of pancreatitis, whichever age is younger.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peutz-Jeghers Syndrome</arm_group_label>
    <description>At least 30 years old, and
at least 2 of 3 criteria diagnostic of Peutz-Jeghers syndrome (characteristic intestinal hamartomatous polyps, mucocutaneous melanin deposition, or family history of Peutz-Jeghers syndrome), or,
known STK11 gene mutation carrier</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Negative control</arm_group_label>
    <description>are undergoing Endoscopic Ultrasound (EUS) and/or Endoscopic Retrograde Cholangiopancreatography (ERCP) for non-pancreatic indications as part of their standard medical care, and
have no clinical or radiologic suspicion of pancreatic disease (chronic pancreatitis or pancreatic cancer)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic Pancreatitis</arm_group_label>
    <description>are undergoing EUS and/or ERCP for evaluation and/or treatment of suspected or proven chronic pancreatitis as part of their standard medical care, and,
have no clinical or radiologic suspicion of pancreatic cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pancreas cancer</arm_group_label>
    <description>a. are undergoing EUS and/or ERCP for evaluation and/or treatment of suspected or proven pancreatic ductal adenocarcinoma (based on clinical and radiologic evidence)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pancreas cyst, IPMN evaluation</arm_group_label>
    <description>are undergoing EUS and/or ERCP for evaluation and/or treatment of suspected or proven pancreatic cancer precursor, intraductal papillary mucinous neoplasm (based on clinical presentation and radiologic or prior EUS or radiologic evidence of a dilated main pancreatic duct and/or pancreatic cystic lesion communicating with the pancreatic ductal system).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human synthetic secretin</intervention_name>
    <description>I.V. bolus of 0.2 mcg/kg secretin given to induce pancreas juice secretion. This intervention offered for all cohorts</description>
    <arm_group_label>Familial pancreas cancer relatives</arm_group_label>
    <arm_group_label>Group 1 germline mutation carrier</arm_group_label>
    <arm_group_label>Group 2 germline mutation carrier</arm_group_label>
    <arm_group_label>Hereditary pancreatitis</arm_group_label>
    <arm_group_label>Peutz-Jeghers Syndrome</arm_group_label>
    <arm_group_label>Negative control</arm_group_label>
    <arm_group_label>Chronic Pancreatitis</arm_group_label>
    <arm_group_label>Pancreas cancer</arm_group_label>
    <arm_group_label>Pancreas cyst, IPMN evaluation</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      approximately 40 ml of blood approximately 5-20 ml pancreas juice approximately 10 ml saliva
      (optional) pancreas cyst fluid (if available)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals at elevated risk for developing pancreas cancer
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hereditary Pancreatitis or

          -  Peutz-Jeghers Syndrome or

          -  Strong family history of pancreas cancer on one side of the family tree or

          -  Confirmed germline mutation carrier (BRCA2, FAMMM, PALB2, BRCA1, HNPCC, PRSS1/2, or
             CTRC

          -  Endoscopic evaluation of pancreas scheduled

        Exclusion Criteria:

          -  Medical comorbidities or coagulopathy that contraindicate endoscopy

          -  Prior surgery that prevent optimal endoscopic ultrasound such as partial or complete
             gastrectomy with Bilroth or Roux-en-Y anastomosis

          -  Stricture or obstruction in the upper GI tract that does not allow passage of the
             echoendoscope

          -  Poor performance status

          -  Inability to provide informed consent

          -  Pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Goggins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hilary Cosby, RN</last_name>
    <email>hcosby1@jhmi.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Clerkin, RN</last_name>
      <email>Barbara.Clerkin@YNHH.ORG</email>
    </contact>
    <investigator>
      <last_name>James Farrell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hilary Cosby, RN, CGRN</last_name>
      <phone>410-502-2893</phone>
      <email>hcosby1@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Goggins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Center, Harvard University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audrey Madigan</last_name>
      <email>AudreyP_Madigan@DFCI.Harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Chinedu Ukaegbu</last_name>
      <email>chinedu_ukaegbu@dfci.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Sapna Syngal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrew Rhim, MD</last_name>
      <email>arhim@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Rhim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fay Kastrinos, MD</last_name>
      <email>fk18@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Fay Kastrinos, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Case Comprehensive Cancer Center, Case Western Medical Reserve</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Furrey, RN</last_name>
      <phone>216-844-7314</phone>
      <email>nancy.furey@uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Amitabh Chak, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maureen DeMarshall, RN</last_name>
      <phone>215-349-8546</phone>
      <email>demarshm@mail.med.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Diego Rodriguez</last_name>
      <email>diego.rodriguez@uphs.upenn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Anil Rustgi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Dudley</last_name>
      <email>dudleyre@mail.magee.edu</email>
    </contact>
    <contact_backup>
      <last_name>Randall Brand, MD</last_name>
      <email>brandre@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Randy Brand, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2013</study_first_submitted>
  <study_first_submitted_qc>November 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2013</study_first_posted>
  <last_update_submitted>December 5, 2017</last_update_submitted>
  <last_update_submitted_qc>December 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>familial pancreas cancer</keyword>
  <keyword>(Peutz-Jeghers Syndrome) PJS</keyword>
  <keyword>Breast cancer (BRCA) 2</keyword>
  <keyword>Partner and Locator of BRCA2 (PALB2)</keyword>
  <keyword>Familial Atypical Multiple Mole- Melanoma (FAMMM)</keyword>
  <keyword>p16</keyword>
  <keyword>Breast Cancer (BRCA)1</keyword>
  <keyword>(hereditary non-polyposis colorectal cancer or Lynch syndrome) HNPCC</keyword>
  <keyword>Lynch Syndrome</keyword>
  <keyword>hereditary pancreatitis</keyword>
  <keyword>Protease Serine (PRSS)</keyword>
  <keyword>Chymotrypsin C (CTRC)</keyword>
  <keyword>Ataxia Telangiectasia Mutated(ATM)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms, Hereditary Nonpolyposis</mesh_term>
    <mesh_term>Peutz-Jeghers Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancrelipase</mesh_term>
    <mesh_term>Pancreatin</mesh_term>
    <mesh_term>Secretin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

